Relapsing Multiple Sclerosis (RMS)
Symptoms, Doctors, Treatments, Advances & More

Relapsing Multiple Sclerosis (RMS) Overview

Save information for later
Sign Up

Learn About Relapsing Multiple Sclerosis (RMS)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Relapsing Multiple Sclerosis (RMS) Local Doctors?
Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis Center

1600 East Jefferson Street, 
Seattle, WA 
Languages Spoken:
English, Croatian, Spanish
Offers Telehealth

Dr. Pavle Repovic is a Neurologist at the Swedish Neuroscience Institute that specializes in the treatment of Multiple Sclerosis. He offers his patients the guidance and support to effectively manage their condition and lead a fuller life. In his spare time he is interested in foreign languages, cultures and cuisine; tango and nature. Dr. Repovic was also selected by Seattle Magazine as a Top Doctor in Neurology. Dr. Repovic is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Neuromyelitis Optica, and Optic Neuritis. Dr. Repovic is board certified in American Board Of Psychiatry And Neurology.

Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Cleveland Clinic Main Campus

1950 East 89th Street, 
Cleveland, OH 
Languages Spoken:
English, Spanish
Offers Telehealth

Daniel Ontaneda is a Neurologist practicing medicine in Cleveland, Ohio. Dr. Ontaneda is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Encephalitis. Dr. Ontaneda is board certified in American Board Of Psychiatry And Neurology, 2010.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Relapsing Multiple Sclerosis (RMS)
Elite in Relapsing Multiple Sclerosis (RMS)

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Neurologist Scott Newsome specializes in the care of patients with neuroimmunological and neuroinflammatory disorders of the central nervous system. He works within the Division of Neuroimmunology and Neurological Infections at The Johns Hopkins Hospital, and has special interest in evaluating and treating patients with multiple sclerosis, transverse myelitis, neuromyelitis optica and stiff person syndrome. After completing fellowship training, Dr. Newsome joined the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers, and he is the director of the Johns Hopkins Neurosciences Consultation and Infusion Center and the Stiff Person Syndrome Center. He is also director of the Johns Hopkins Neuroimmunology and Neurological Infectious Disease Fellowship Program and co-director of the Multiple Sclerosis Experimental Therapeutics Program. Dr. Newsome received his medical degree from the New York College of Osteopathic Medicine, with honors. During his neurology residency, he was awarded the Golden Apple Outstanding Resident Teaching Award, and later was chosen to be chief resident. He subsequently completed a fellowship in neuroimmunology at The Johns Hopkins Hospital with the support of a Sylvia Lawry Physician Fellowship Award from the National Multiple Sclerosis Society. Identifying and testing novel therapies and therapeutic strategies for multiple sclerosis and other neuroimmunological disorders is Dr. Newsome’s main research focus. Other research endeavors include validating the use of new quantitative clinical outcome measures and imaging techniques in multiple sclerosis and identifying risk factors of disease onset and severity, response to treatment and long-term outcomes in neuroimmunological disorders. An adviser for the National Multiple Sclerosis Society and a member of the Miller-Coulson Academy of Clinical Excellence, Dr. Newsome has also served as president of the Consortium of Multiple Sclerosis Centers. Dr. Newsome is rated as an Elite provider by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Stiff Person Syndrome, Multiple Sclerosis (MS), Transverse Myelitis, and Relapsing Multiple Sclerosis (RMS). Dr. Newsome is board certified in American Board Of Psychiatry And Neurology.

What are the latest Relapsing Multiple Sclerosis (RMS) Clinical Trials?
Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)

Summary: This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, an...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis

Summary: This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period. Eligible participants may choose to continue treatment with fenebrutinib in the optional extension period after completing the dose exploration period.